NAD+ vs SS-31
Extensively Studied vs Well Studied
synergistic Both support mitochondrial function through different mechanisms.
Molecular Data
NAD+ SS-31
Weight 663.43 Da —
Half-life 1-4 hours (intracellular) ~2 hours
Type Coenzyme Aromatic-cationic tetrapeptide
Key Benefits
NAD+
01 Restores mitochondrial function and ATP synthesis
02 Enhances glucose and fat metabolism
03 Improves oxygen utilization and endurance
04 Activates DNA repair mechanisms
05 Supports longevity pathways via sirtuins
06 Improves mental clarity and focus
SS-31
01 Directly protects mitochondria
02 Improves cellular energy production (ATP)
03 Reduces oxidative damage
04 Enhances exercise capacity
05 Excellent safety profile in clinical trials
06 Cardioprotective effects
Dosing Protocols
NAD+
IV: 250-1000mg; IM/SubQ: 100-500mg; Intranasal: 25-50mg; Oral precursors: 100-500mg NMN/NR / IV: 1-2x weekly; IM/SubQ: 2-3x weekly; Intranasal: 1-2x daily; Oral: daily
IV Infusion 250-1000mg 1-2x weekly
IM/SubQ 100-500mg 2-3x weekly
SS-31
5-10mg general support, 10-40mg clinical/performance protocols / Once daily (morning or pre-workout for athletic use)
General mitochondrial support 5-10mg Once daily
Athletic performance 10-20mg Once daily pre-workout
Clinical protocols 40mg Once daily
Acute cardioprotection 0.25mg/kg/hr Continuous infusion
Side Effects
NAD+
Mild flushing during IV infusion
Temporary nausea
SS-31
Excellent safety profile in clinical trials
No significant side effects reported at therapeutic doses
Mild injection site reactions possible
Safe for long-term use based on current data
Contraindications
IV administration requires medical supervision
Avoid alcohol during treatment
Maintain consistent dosing schedule
Known hypersensitivity to peptides
Pregnancy or breastfeeding (limited data)
Research Evidence
NAD+ SS-31
Status Extensively Studied Well Studied
References 4 studies 4 studies
Latest — February 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.